P-WAVE TERMINAL FORCE IN LEAD V1-MORRIS INDEX AFTER CATHETER ABLATION: A STUDY IN ATRIAL FIBRILLATION AND TYPICAL ATRIAL FLUTTER PATIENTS

Introduction: P-wave terminal force in lead V1 (PTFV1, Morris Index) is a marker of atrial remodeling. We evaluated its role three months after atrial fibrillation (AF) or cavotricuspid isthmus (CTI) ablation. Methods: A total of 120 AF patients (46% persistent, 54% paroxysmal) and 58 CTI patients were analyzed. PTFV1 was measured pre-ablation and at three months. Abnormal PTFV1 was defined as ≥|0.04| mV·s. Patients were followed for 12 months. Endpoints were AF/AT recurrence in the AF cohort and new AF in the CTI cohort. Results: In the AF cohort, recurrence occurred in 31%. Abnormal 3-month PTFV1 predicted higher recurrence (46% vs. 21%; HR 2.05, 95% CI 1.22–3.46). Addition of PTFV1 improved AUC from 0.67 to 0.76. In the CTI cohort, new AF occurred in 15%, but abnormal PTFV1 was not predictive (OR 1.8, 95% CI 0.8–4.2). Lead II P-wave duration was significant. Conclusion: Three-month PTFV1 is a robust predictor of AF recurrence after ablation. Its role in CTI ablation is limited.

Authors

Publication Details

Journal
Eskisehir Medical Journal Eskisehir City Hospital
Published
2026-03-04
DOI
https://doi.org/10.48176/esmj.2026.249
Primary Topic
Atrial Fibrillation Management and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-WAVE TERMINAL FORCE IN LEAD V1-MORRIS INDEX AFTER CATHETER ABLATION: A STUDY IN ATRIAL FIBRILLATION AND TYPICAL ATRIAL FLUTTER PATIENTS

Serdar Soner, Gamze Yeter Arslan
Eskisehir Medical Journal Eskisehir City Hospital
Atrial Fibrillation Management and Outcomes
article

P-WAVE TERMINAL FORCE IN LEAD V1-MORRIS INDEX AFTER CATHETER ABLATION: A STUDY IN ATRIAL FIBRILLATION AND TYPICAL ATRIAL FLUTTER PATIENTS

Serdar Soner, Gamze Yeter Arslan
article en

Abstract

Introduction: P-wave terminal force in lead V1 (PTFV1, Morris Index) is a marker of atrial remodeling. We evaluated its role three months after atrial fibrillation (AF) or cavotricuspid isthmus (CTI) ablation. Methods: A total of 120 AF patients (46% persistent, 54% paroxysmal) and 58 CTI patients were analyzed. PTFV1 was measured pre-ablation and at three months. Abnormal PTFV1 was defined as ≥|0.04| mV·s. Patients were followed for 12 months. Endpoints were AF/AT recurrence in the AF cohort and new AF in the CTI cohort. Results: In the AF cohort, recurrence occurred in 31%. Abnormal 3-month PTFV1 predicted higher recurrence (46% vs. 21%; HR 2.05, 95% CI 1.22–3.46). Addition of PTFV1 improved AUC from 0.67 to 0.76. In the CTI cohort, new AF occurred in 15%, but abnormal PTFV1 was not predictive (OR 1.8, 95% CI 0.8–4.2). Lead II P-wave duration was significant. Conclusion: Three-month PTFV1 is a robust predictor of AF recurrence after ablation. Its role in CTI ablation is limited.

Eskisehir Medical Journal Eskisehir City Hospital
Openalex Percentile: Top 41%
Atrial Fibrillation Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.